AACR 2021 | Overcoming resistance to PARPi in BRCA1-deficient breast cancer with STING agonists

The use of PARP inhibitors (PARPi) has impacted the treatment landscape of patients with cancer haboring BRCA mutations. In this video, Qiwei Wang, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses a major mechanism by which BRCA1-deficient breast tumors progress during PARP inhibition and the role of tumor-associated macrophages in this phenomenon, which explains the differences in clinical outcomes to PARP inhibition observed in breast cancer in comparison to ovarian tumors. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.